GLP-1 Drug Industry Research Report 2025

The global market for GLP-1–based prescription therapeutics expanded to US$54,015.22 million in 2024 and is forecast to reach US$482,068.71 million by 2031. Growth is overwhelmingly volume-led: treated patient-months rise from 106,199.35 thousand in 2024 to 886,728.17 thousand by 2031 (2025–2031 CAGR 34.51%), while the global average realized net price per patient-month remains broadly stable around the low-US$500s, edging from US$508.62 in 2024 to US$543.65 in 2031 (2025–2031 CAGR 0.93%). Long-acting agents define the category. They account for 94.8% of 2024 revenue (US$51,185.09 million) and 92.5% of patient-months, and are projected to capture 99.6% of revenue and 99.4% of patient-months by 2031, as daily formulations normalize into a durable but small tail.

By clinical application, type 2 diabetes remains the anchor of demand and value, contributing US$31,118.80 million in 2024 (57.6% share) and an estimated US$302,964.94 million by 2031 (62.8% share; 2025–2031 CAGR 35.94%). Cardiovascular-risk reduction adds a second pillar with US$15,981.61 million in 2024 and US$94,741.75 million by 2031 (share ~19.6%; CAGR 29.13%) as guideline adoption broadens. Obesity is the fastest-compounding use case, increasing from US$6,914.81 million in 2024 to US$84,362.02 million by 2031 (CAGR 46.51%); pricing bands sit near type-2-diabetes levels, so value growth tracks patient-month accumulation rather than list-price inflation.

Regional dynamics remain asymmetric but consistent with scale-up. North America generates the majority of absolute revenue and is expected to grow from US$37,022.03 million in 2024 (68.6% of global revenue) to US$324,554.51 million by 2031 (67.3% share; 2025–2031 CAGR 35.82%), supported by rapid initiation, strong persistence, and mature coverage frameworks. Europe increases from US$8,939.52 million to US$83,227.41 million over the same period (share rising from 16.6% to 17.3%; CAGR 34.94%) as reimbursement widens and delivery constraints ease. Asia Pacific scales from US$7,054.39 million to US$66,380.86 million (share from 13.1% to 13.8%; CAGR 36.85%) as local access pathways, hospital procurement norms, and cold-chain infrastructure adapt to weekly volume. South America and the Middle East & Africa together remain small in value terms but grow from a combined US$999.28 million in 2024 to US$7,905.93 million by 2031 as tenders and public coverage expand.

Industry structure is highly concentrated and capacity-driven. In 2024 Novo Nordisk and Eli Lilly together accounted for the vast majority of global GLP-1 revenue, at US$31,752.39 million and US$21,719.30 million respectively, with all other participants materially smaller. The mix reflects the dominance of weekly semaglutide and dulaglutide franchises alongside the rapid emergence of next-generation incretin programs that build on a GLP-1 backbone. Manufacturing scale in peptide synthesis, device/pen assembly, and sterile fill-finish remains the near-term governor of growth; as new trains, sites, and CDMO partnerships come online, deferred prescriptions convert to active therapy and persistence on treatment becomes the primary determinant of patient-months treated.

Figures reported in this study measure the commercial market for GLP-1–pathway therapeutics using a consistent accounting framework. Volumes are expressed as patient-months treated (PMT) at labeled maintenance dosing for each formulation, prices as realized net ex-manufacturer US$ per PMT, and revenues as the product of PMT and net price. The quantified core covers single-agonist GLP-1 receptor agonists across all approved formulations and dosing cadences, including semaglutide (Ozempic, Rybelsus, Wegovy), liraglutide (Victoza, Saxenda, and authorized/generic liraglutide, including the fixed-ratio combination IDegLira/Xultophy), dulaglutide (Trulicity), exenatide IR/ER (Byetta, Bydureon, Bydureon BCise), lixisenatide (Adlyxin/Lyxumia and iGlarLixi/Soliqua/Suliqua), and regionally marketed GLP-1RAs such as PEG-loxenatide and beinaglutide. Fixed-ratio combinations that contain a GLP-1RA are included with ring-fencing to avoid double counting. Dual/multi-incretin agonists with a GLP-1 component are covered qualitatively in competitive and substitution analyses but are not added to core market totals unless stated. Results are segmented by Type (Short-acting vs Long-acting), by Indication (type 2 diabetes, obesity/weight management, cardiovascular-risk reduction), by company/product, and by region and country. Historical series span 2020–2024 with 2024 as the base year; forecasts cover 2025–2031. All currency values are nominal US dollars. The scope and methods ensure that totals are internally consistent and comparable across time and geographies, enabling decision-grade tracking of a market whose expansion is determined primarily by initiation velocity, persistence, and supply throughput rather than by net price escalation.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for GLP-1 Drug sales, projected growth trends, production technology, application and end-user industry.

Novo Nordisk

Eli Lilly

Sanofi

Teva

Jiangsu Hansoh Pharmaceutical

Huadong Medicine

Benemae Pharmaceutical

Tonghua Dongbao Pharma

Chia Tai-Tianqing Pharmaceutical

AstraZeneca

Short-acting

Long-acting

GLP-1 Drug Segment by Indications

T2D

CV risk

Obesity

North America

United States

Canada

Mexico

Europe

Germany

United Kingdom

France

Italy

Spain

Netherlands

Poland

Sweden

Rest of Europe

South America

Brazil

Argentina

Chile

Colombia

Peru

Ecuador

Uruguay

Paraguay

Rest of South America

MEA

Saudi Arabia

United Arab Emirates

Israel

South Africa

Egypt

Kuwait

Rest of the MEA

Reasons for Doing This Study

This study is undertaken to provide an independent, decision-grade assessment of the GLP-1 pathway market—encompassing single-agonist GLP-1 receptor agonists and GLP-1–based dual or multi-agonists—at a time when scientific read-outs, regulatory momentum, and industrial scale are jointly reshaping market structure. Indications, delivery formats, and supply chains are in flux, while public sources often conflate classes, mix list and net prices, and apply inconsistent volume units, obscuring where value will concentrate and how competitive positions may shift.

By fixing a clear taxonomy for the GLP-1 pathway, normalizing volumes to patient-months treated (k PMT), using net ex-manufacturer price as the price construct, and allocating revenues to the product actually dispensed—including fixed-ratio combinations while preventing double counting—the report creates a coherent, comparable time series. Segmentations are reported by class (GLP-1-only vs GLP-1–based dual/multi-agonists), type (short-acting vs long-acting), indication (type 2 diabetes, obesity/weight management, labeled cardiovascular risk reduction, OSA where applicable), company/product, and region.

In addition, explicit inclusion rules and scenario triggers are defined around manufacturing de-bottlenecking, access and reimbursement adoption, and label-expansion sequencing. The result is a consistent evidence base that supports decisions on capacity build-out, market-access strategy, competitive positioning, and partnering.

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of GLP-1 Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of GLP-1 Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of GLP-1 Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by indications, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.